Teracyte Analytics

TeraCyte developed a platform for high throughput temporal analysis of live single-cells, based on proprietary array chips, an imaging system and analytical tools. The platform allows for capturing and retaining suspension cells in dedicated cell arrays and real-time monitoring of cell function with high sensitivity fluorescent imaging and a matching high resolution brightfield image. TeraCyte’s AI models can distinguish between various cell types, count cells and identify cell-cell interactions. TeraCyte’s solution can be used for discovery, development and manufacturing of cell therapies, biological and small molecule drugs. TeraCyte is currently set to begin collaborations with cell therapy companies on the development of high value applications.

Teracyte Analytics has raised $1.5M in total funding across 1 rounds. The company is currently at the Seed stage. Key investors include Israel Innovation Authority .

Teracyte Analytics was founded in 2020 by Yoav Nissan-cohen (Co-founder & CEO), Gal Lenz (Co-founder & CTO).

Teracyte Analytics operates in Health Tech & Life Sciences, Pharma & Medical Biotechnology, Drugs Discovery & Development, with core technologies in Simulation & Imaging, Semiconductors & Electronics, Chipsets, Artificial Intelligence. Target customers: Healthcare & Life Sciences, Life Sciences, Biotechnology, Pharmaceuticals.

Teracyte Analytics is based in Ha-Tokhen St 17, Caesarea, 3079892, Israel.